Compare ELTX & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELTX | KINS |
|---|---|---|
| Founded | 2011 | 1886 |
| Country | United States | United States |
| Employees | 33 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 205.7M |
| IPO Year | 2014 | 2013 |
| Metric | ELTX | KINS |
|---|---|---|
| Price | $9.91 | $15.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | 112.2K | ★ 133.2K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | 39.29 | ★ 94.59 |
| EPS | N/A | ★ 2.88 |
| Revenue | $2,301,000.00 | ★ $214,867,301.00 |
| Revenue This Year | N/A | $24.23 |
| Revenue Next Year | N/A | $18.05 |
| P/E Ratio | ★ N/A | $5.61 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $5.80 | $13.08 |
| 52 Week High | $14.93 | $19.42 |
| Indicator | ELTX | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 42.66 |
| Support Level | $8.76 | $14.13 |
| Resistance Level | $10.16 | $17.06 |
| Average True Range (ATR) | 0.75 | 0.76 |
| MACD | -0.19 | -0.23 |
| Stochastic Oscillator | 2.14 | 9.20 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.